Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/62577
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Pinho, Vanessa | por |
dc.contributor.author | Fernandes, Mário | por |
dc.contributor.author | da Costa, André | por |
dc.contributor.author | Machado, Raul | por |
dc.contributor.author | Gomes, Andreia C | por |
dc.date.accessioned | 2019-12-06T10:02:25Z | - |
dc.date.available | 2023-01-01T07:00:52Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1359-6101 | por |
dc.identifier.uri | https://hdl.handle.net/1822/62577 | - |
dc.description | "In Press, Journal Pre-proof" | por |
dc.description.abstract | Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with several functions in health and disease ranging from inflammation to cancer. LIF is also a potential target and/or therapeutic agent for diseases such as multiple sclerosis, stroke and even psychological disorders, where the function of LIF as a neurotrophic factor has only recently been explored. In recent years, a limited number of LIF clinical trials have been completed, which partially explains the shortage of effective applications as a therapeutic agent. With the increasing interest from biotechnology companies producing recombinant LIF, this status quo will certainly change, and the potential impact of LIF in terms of disease diagnosis, treatment and management will be realized. | por |
dc.description.sponsorship | This work was supported by national funds through the fct i.p. and by the erdf through the compete2020 - programa operacional competitividade e internacionalização (POCI) with the strategic program UID/BIA/04050/2019 (poci-01-0145-feder-007569). We also acknowledge support from fct within the fun2cyt project with the grant poci-01-0145-feder-030568. | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier 1 | por |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FBIA%2F04050%2F2019/PT | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | por |
dc.subject | LIF | por |
dc.subject | Multiple sclerosis | por |
dc.subject | Cytokine | por |
dc.subject | Astrocytes | por |
dc.subject | Brain injury | por |
dc.subject | Myelination | por |
dc.subject | Stroke | por |
dc.title | Leukemia inhibitory factor: recent advances and implications in biotechnology | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1359610119301145 | por |
oaire.citationStartPage | 25 | por |
oaire.citationEndPage | 33 | por |
oaire.citationVolume | 52 | por |
dc.identifier.eissn | 1879-0305 | por |
dc.identifier.doi | 10.1016/j.cytogfr.2019.11.005 | por |
rcaap.embargofct | copyright da editora | por |
dc.identifier.pmid | 31870618 | por |
dc.subject.fos | Ciências Médicas::Biotecnologia Médica | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Cytokine & Growth Factor Reviews | por |
oaire.version | AM | por |
Aparece nas coleções: | CBMA - Artigos/Papers DBio - Artigos/Papers |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
1-s2.0-S1359610119301145-main.pdf | 2,41 MB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons